Attenua Overview
- Year Founded
-
2015
- Status
-
Acquired/Merged
- Latest Deal Type
-
M&A
Attenua General Information
Description
Developer of medicines intended for patients who suffer from chronic respiratory disorders. The company develops novel medicines for patients who suffer from chronic respiratory disorders such as chronic cough, enabling patients to live a healthy life.
Contact Information
Website
www.attenua.comCorporate Office
- C/o Benjamin Potter/Latham and Watkins, 140 Scott Drive
- Menlo Park, CA 94025
- United States
Corporate Office
- C/o Benjamin Potter/Latham and Watkins, 140 Scott Drive
- Menlo Park, CA 94025
- United States
Attenua Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 2. Merger/Acquisition | 05-Feb-2020 | Completed | Clinical Trials - Phase 2 | |||
| 1. Early Stage VC (Series A) | 30-Apr-2018 | Completed | Clinical Trials - Phase 2 |
Attenua Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate ($) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series A2 | ||||||||
| Series A1 |
Attenua Comparisons
Industry
Financing
Details
Attenua Competitors (1)
One of Attenua’s competitors is NeRRe Therapeutics, a Venture Capital-Backed company based in Stevenage, United Kingdom.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| NeRRe Therapeutics | Venture Capital-Backed | Stevenage, United Kingdom |
Attenua Patents
Attenua Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2018152554-A1 | Antitussive compositions and methods | Inactive | 22-May-2017 | ||
| WO-2017070235-A1 | Antitussive compositions and methods | Inactive | 19-Oct-2015 | ||
| AU-2016302769-A1 | Antitussive compositions and methods | Inactive | 31-Jul-2015 | ||
| CA-2994150-A1 | Antitussive compositions and methods | Inactive | 31-Jul-2015 | ||
| EP-3328383-A1 | Antitussive compositions and methods | Inactive | 31-Jul-2015 | A61K31/439 |
Attenua Former Investors (4)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Abingworth | Venture Capital | Minority | ||
| Omega Funds | Venture Capital | Minority | ||
| OrbiMed | Growth/Expansion | Minority | ||
| Redmile Group | Venture Capital | Minority |
Attenua Investments (1)
Attenua’s most recent deal was a Corporate Asset Purchase with Catalyst Biosciences (oral neural nicotinic receptor assets) for . The deal was made on 01-Aug-2016.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Catalyst Biosciences (oral neural nicotinic receptor assets) | 01-Aug-2016 | Corporate Asset Purchase | Buildings and Property |
Attenua FAQs
-
When was Attenua founded?
Attenua was founded in 2015.
-
Where is Attenua headquartered?
Attenua is headquartered in Menlo Park, CA.
-
What industry is Attenua in?
Attenua’s primary industry is Drug Discovery.
-
Is Attenua a private or public company?
Attenua is a Private company.
-
What is Attenua’s current revenue?
The current revenue for Attenua is .
-
How much funding has Attenua raised over time?
Attenua has raised $35M.
-
Who are Attenua’s investors?
Abingworth, Omega Funds, OrbiMed, and Redmile Group have invested in Attenua.
-
Who are Attenua’s competitors?
NeRRe Therapeutics is a competitor of Attenua.
-
When was Attenua acquired?
Attenua was acquired on 05-Feb-2020.
-
Who acquired Attenua?
Attenua was acquired by Coda Biotherapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process